https://bio.nikkeibp.co.jp/atcl/news/p1/25/04/17/13212/

https://www.nature.com/articles/s41586-025-08700-0

Kyoto University Hospital recently announced that it had obtained data on safety and efficacy in an investigator-initiated clinical trial of allogeneic iPS cell-derived dopamine neural progenitor cell transplantation for Parkinson’s disease, which began in 2018.

In terms of efficacy, the secondary endpoint, motor function improved during the drug treatment break in four of the six patients evaluated. The average change from baseline in the Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), which evaluates the condition of Parkinson’s disease, was 20.4% 24 months after transplantation. Motor function during drug treatment improved by an average of 35.7% in five patients.

Sumitomo Pharma aims to commercialize these allogeneic iPS cell-derived dopamine neural progenitor cells (development number: CT1-DAP001/DSP-1083) and will apply for approval within fiscal year 2025.